Basalin is a sterile, clear, colourless solution of insulin glargine labelled at 100 IU/mL for subcutaneous injection in type 1 and type 2 diabetes mellitus. The product model described here is the 100 IU/mL formulation in a 3 mL pre-filled pen containing 300 IU of insulin glargine per device; a 10 mL multi-dose vial is available in some regulatory filings. Each millilitre contains 3.6378 mg insulin glargine, 30 µg zinc as zinc chloride, 2.7 mg m-cresol as antimicrobial preservative, 17 mg glycerol as tonicity-adjusting agent, and water for injections. The pH is adjusted to approximately 4.0 with hydrochloric acid and sodium hydroxide. Insulin glargine has the molecular formula C267H404N72O78S6 and a molecular mass of approximately 6063 Da. The commercial descriptor “Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable” is not pharmacopoeially applicable to native insulin glargine in conventional solid oral form; the peptide is susceptible to gastrointestinal proteolysis and has negligible oral bioavailability. Basalin is therefore an injectable parenteral dosage form, not a tablet, capsule, or granule intermediate.

What Limits Insulin Glargine to Injectable Delivery?

The A21 glycine substitution and the two arginine residues at the C-terminus of the B-chain shift the isoelectric point from approximately 5.3 for human insulin to approximately 6.7–7.0 for insulin glargine. This makes the molecule soluble at the acidic formulation pH but causes precipitation in the neutral subcutaneous interstitium. Oral administration is not viable for the unmodified peptide because the 6063 Da molecular mass exceeds the passive permeability range of the intestinal epithelium, and gastric pepsin, pancreatic trypsin, chymotrypsin, and brush-border peptidases degrade the molecule. Enteric coating alone does not overcome the permeability barrier. Investigational oral peptide systems using penetration enhancers, enzyme inhibitors, or nanocarriers are not approved for insulin glargine. No Ph. Eur. or USP monograph defines a tablet, capsule, or granule dosage form for native insulin glargine. Published data for a Basalin-specific oral solid formulation is limited; the recognized route for this product is subcutaneous injection.

After subcutaneous injection, absorption from the glargine depot is dissolution-limited. Published time-action data describe onset of glucose-lowering activity at approximately 1–2 h, a relatively flat profile without a pronounced peak, and duration of approximately 24 h. The injection should be administered into the thigh, upper arm, or abdomen, with site rotation to reduce lipodystrophy and absorption variability. Basalin must not be given intravenously or intramuscularly. Continuous subcutaneous insulin infusion is not approved for this presentation because the acid-vehicle glargine solution can precipitate in neutral-pH pump tubing and produce catheter occlusion.

Because Basalin is a basal insulin, it is not used to cover prandial glucose excursions. Rapid-acting insulin analogues such as insulin lispro, insulin aspart, or insulin glulisine have onset times below 0.5 h and are used separately at meals. Mixing these with glargine in the same syringe is not recommended because the pH 4.0 glargine vehicle can precipitate other insulin species and alter the glargine depot. The basal component is usually injected once daily at the same time each day.

Release Parameter Boundaries and Primary Packaging for 3 mL Cartridges

Primary packaging consists of type I borosilicate glass cartridges or vials sealed with halobutyl rubber closures and aluminium overseals. Pre-filled pen devices must satisfy ISO 11608-1:2022 for dose accuracy, force, and mechanical function. Cartridge siliconisation is controlled because insufficient silicone increases plunger friction and excessive silicone can generate subvisible particles. Batch release testing includes identity by peptide mapping, potency by liquid chromatography against an insulin glargine reference standard, related proteins and high-molecular-weight proteins by size-exclusion HPLC, pH by Ph. Eur. 2.2.3, osmolality by Ph. Eur. 2.2.35, zinc content by atomic absorption spectrometry under Ph. Eur. 2.2.23, m-cresol content by HPLC, visible and subvisible particles by Ph. Eur. 2.9.19 or USP <788>, bacterial endotoxins by Ph. Eur. 2.6.14 or USP <85>, and sterility by Ph. Eur. 2.6.1 or USP <71>. The unopened product is stored at 2–8 °C and protected from light. Freezing must be avoided because ice-crystal denaturation and subsequent aggregation can impair bioavailability. After first use, the pen or vial is kept at no more than 30 °C for a maximum of 28 days; remaining contents are then discarded. Manufacture uses aseptic filtration because terminal steam sterilisation would degrade the peptide. pH adjustment and zinc addition are performed at 4–8 °C with slow mixing to prevent local precipitation near the glargine isoelectric point. Stability-indicating methods align with ICH Q6B expectations for biological products; public regulatory summaries may not disclose exact brand-specific limits for high-molecular-weight proteins and related proteins.

On production-scale 3 mL cartridge filling lines, the main process-control points are bulk-hold temperature, dissolved oxygen, and siliconisation uniformity. Bulk solution is kept at 2–8 °C under nitrogen blanketing, with hold time validated to prevent deamidation and disulfide scrambling that would increase high-molecular-weight proteins. Visible particle defects have been observed when needle-shield elastomer fragments or excess silicone are introduced during device assembly; 100% visual inspection and AQL sampling are therefore applied. Freeze-thaw studies are not part of routine distribution because the product is not intended for freezing; accidental freezing requires discard. Published production data for the Basalin brand specifically is limited, but these controls are consistent with standard practice for acidic insulin glargine solutions.

The antimicrobial preservative m-cresol at 2.7 mg/mL gives multidose cartridge and vial integrity; it is also a potential contact sensitizer. Injection-site pain and erythema may be attributable to m-cresol or the acidic pH. The incidence of true m-cresol allergy is low but documented; hypoallergenic preparations are not available for insulin glargine. Zinc at 30 µg/mL stabilises the hexameric structure in solution. Upon dilution or neutralisation, zinc coordination changes; this is why mixing Basalin with other insulins or diluents may produce unpredictable precipitation.

If a 300 IU/mL Glargine Product Is Available, Why Not Substitute It?

Basalin 100 IU/mL differs from insulin glargine 300 IU/mL in injection volume, depot geometry, and absorption kinetics. The 100 IU/mL product has an onset of approximately 1–2 h and a duration of approximately 24 h; the 300 IU/mL product has a more gradual and prolonged profile that is not directly interchangeable on a unit-per-unit basis. Basalin also differs from NPH insulin, which is a resuspension-requiring suspension with a pronounced peak at 4–8 h. Insulin detemir relies on albumin binding, while insulin degludec forms soluble multi-hexamer chains with a duration beyond 42 h. The following table provides representative published time-action boundaries for basal insulin classes.

Switching between Basalin 100 IU/mL and another basal insulin requires dose retitration and clinical monitoring. Published regulatory guidance generally recommends that when a patient transfers from twice-daily NPH insulin to once-daily insulin glargine, the starting glargine dose may be reduced by approximately 20% from the total daily NPH dose to reduce nocturnal hypoglycemia; subsequent adjustment is based on fasting plasma glucose. Basalin-specific labelling may vary by jurisdiction. The product must not be diluted or mixed with other insulins in the same syringe because the pH 4.0 vehicle can precipitate other insulin species and alter the glargine depot formation. Use a 4 mm, 5 mm, or 6 mm pen needle appropriate for body habitus and inject at a 90° angle unless clinical judgement indicates a skin lift. Baseline renal, hepatic, and cardiovascular status should be considered because insulin clearance is reduced in renal impairment and basal insulin requirements can change during illness, surgery, or therapy with glucocorticoids. These operational boundaries are part of the product’s safe-use profile.

Clinical monitoring during Basalin initiation includes fasting plasma glucose, HbA1c, and symptomatic hypoglycemia. Dose adjustment is based on fasting glucose, but published guidelines report that fixed-unit adjustment is not appropriate for all patients because insulin sensitivity varies with body weight, renal function, and concomitant therapy. Glucocorticoids, thiazolidinediones, and beta-blockers alter glucose response or mask hypoglycemic symptoms; beta-blockers may blunt adrenergic warning signs. Insulin glargine is not inherently less immunogenic than other insulin analogues; injection-site reactions and generalised hypersensitivity can occur. Local injection-site lipodystrophy can alter release kinetics; hence rotation is required.

Insulin detemir is acylated with a C14 fatty acid, prolonging action through reversible albumin binding and dihexamer formation; it is often administered once or twice daily depending on dose. Insulin glargine 100 IU/mL relies on pH-dependent precipitation, not albumin binding. Published pharmacodynamic clamp studies report lower within-day peak-to-trough variability for insulin glargine compared with NPH insulin. Insulin degludec has a half-life above 25 h and a duration beyond 42 h, allowing flexible once-daily dosing; it forms soluble multi-hexamers. Basalin does not have the same ultra-long profile.

As a subsequent-entry biologics or biosimilar product where registered, Basalin differs from originator insulin glargine by manufacturer, host cell, and downstream purification train; the amino acid sequence is unchanged. Regulatory evaluation under EMA/CHMP biosimilar guidelines, WHO biologicals guidance, or local biosimilar frameworks compares analytical similarity, preclinical data, and clinical immunogenicity. Physicochemical equivalence alone is insufficient to presume therapeutic equivalence. If interchangeability has not been designated in a specific jurisdiction, substitution at the pharmacy level should follow national substitution rules. Published head-to-head clinical efficacy data for Basalin relative to originator insulin glargine is limited; the primary evidence resides in the regulatory dossier and may not be public.